What does CUSIP 92790C104 represent in this 13F holders report?

CUSIP 92790C104 is the security identifier for VRDN - Viridian Therapeutics, Inc.\DE - Common Stock used to aggregate holder disclosures.

How many institutions held VRDN - Viridian Therapeutics, Inc.\DE - Common Stock in Q4 2020?

2 institutional investors reported VRDN - Viridian Therapeutics, Inc.\DE - Common Stock for Q4 2020. Use the holders table for investor-level position and value details.

Viridian Therapeutics, Inc.\DE - Common Stock (VRDN)

CUSIP: 92790C104

Q4 2020 13F Holders as of 31 Dec 2020

Type / Class: Equity / Common Stock
Shares outstanding: 95,489,675
Total 13F shares: 229,000
Share change: +229,000
Total reported value: $3,767,000
Price per share: $16.46
Number of holders: 2
Value change: +$3,767,000
Number of buys: 2

Quarterly Holders Quick Answers

What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.\DE - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2021

Recent filing periods for CUSIP 92790C104:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) as of Q4 2020

As of 31 Dec 2020, Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) was held by 2 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 229,000 shares. The largest 2 holders included Atlas Venture Advisors, Inc. and VR Adviser, LLC. This page lists 2 institutional shareholders reporting positions in this security for the Q4 2020 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2020 vs Q4 2025 Across Filers

Q4 2025 holders

229

Q4 2020 holders

Holder diff

-227

Investor	Q4 2025 Shares	Q4 2020 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q4 2020 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.